Atea Pharmaceuticals (AVIR) Projected to Post Quarterly Earnings on Thursday

Atea Pharmaceuticals (NASDAQ:AVIR) is expected to be releasing its earnings data after the market closes on Thursday, March 6th. Analysts expect Atea Pharmaceuticals to post earnings of ($0.35) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Atea Pharmaceuticals Stock Performance

NASDAQ AVIR opened at $2.90 on Tuesday. Atea Pharmaceuticals has a one year low of $2.75 and a one year high of $4.48. The stock has a 50-day moving average of $3.18 and a 200 day moving average of $3.36. The company has a market capitalization of $244.94 million, a price-to-earnings ratio of -1.40 and a beta of 0.19.

Insider Transactions at Atea Pharmaceuticals

In related news, Director Franklin M. Berger sold 359,606 shares of Atea Pharmaceuticals stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $2.85, for a total value of $1,024,877.10. Following the completion of the sale, the director now owns 451,897 shares of the company’s stock, valued at $1,287,906.45. The trade was a 44.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 17.80% of the company’s stock.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.